{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:41:48Z","timestamp":1788295308338,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006668","name":"Fund for Scientific and Technological Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000592","name":"US-UK Fulbright Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"National Scientific and Technical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007869","name":"National University of the South General Secretariat of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejpb.2025.114870","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T18:08:05Z","timestamp":1758132485000},"page":"114870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Flowrate-Independent indomethacin dry powder inhaler for potential treatment of pediatric asthma: In vitro aerodynamic and anti-inflammatory evaluation"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3539-4922","authenticated-orcid":false,"given":"Nazareth E.","family":"Ceschan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V.","family":"Dugour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-5368","authenticated-orcid":false,"given":"Beatriz","family":"Behrend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh D.C.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Bucal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda V.","family":"Ram\u00edrez Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114870_b0005","first-page":"1","article-title":"Epidemiology of current asthma in children under 18: a two-decade overview using national center for health statistics (NCHS) Data","volume":"15","author":"Ojo","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ejpb.2025.114870_b0010","first-page":"131","article-title":"Clinical profile and triggers of childhood asthma among patients diagnosed at paediatric asthma clinic","author":"Balaji","year":"2020","journal-title":"Kerala Med. J. XIII"},{"key":"10.1016\/j.ejpb.2025.114870_b0015","first-page":"905","article-title":"Evaluation the effect of pulmicort inhalation on children with acute asthma attack","volume":"11","author":"Bahrami","year":"2020","journal-title":"Syst. Rev. Pharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100675","article-title":"Age at asthma diagnosis is related to prevalence and characteristics of asthma symptoms","volume":"15","author":"Hisinger-M\u00f6lk\u00e4nen","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.ejpb.2025.114870_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106949","article-title":"The impact of inhaler technique on clinical outcomes in adolescents and adults with asthma: a systematic review","volume":"202","author":"Roche","year":"2022","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejpb.2025.114870_b0030","first-page":"62","article-title":"Inhaled corticosteroid-phobia and childhood asthma: current understanding and management implications","volume":"33","author":"Hui","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.ejpb.2025.114870_b0035","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/ppul.25838","article-title":"Features of successful interventions to improve adherence to inhaled corticosteroids in children with asthma: a narrative systematic review","volume":"57","author":"Pearce","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ejpb.2025.114870_b0040","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejpb.2025.114870_b0045","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.xphs.2016.05.004","article-title":"Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids","volume":"105","author":"Mukker","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114870_b0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1094-5539(03)00105-6","article-title":"Soft steroids: a new approach to the treatment of inflammatory airways diseases","volume":"16","author":"Belvisi","year":"2003","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2025.114870_b0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003495-199448010-00002","article-title":"Could NSAIDs have a role as antiasthmatic agents?","volume":"48","author":"Bianco","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2025.114870_b0060","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.15258","article-title":"Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19, Allergy: European","volume":"77","author":"Sokolowska","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejpb.2025.114870_b0065","series-title":"Cochrane Database of Systematic Reviews","article-title":"Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis (Review)","author":"Pizzutto","year":"2016"},{"key":"10.1016\/j.ejpb.2025.114870_b0070","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1164\/ajrccm.152.2.7633717","article-title":"Inhaled indomethacin prevents bronchoconstrirtive response to distilled water but not to histamine in children with asthma","volume":"152","author":"Shimizu","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejpb.2025.114870_b0075","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1067\/mai.2000.106212","article-title":"Effect of inhaled indomethacin in asthmatic patients taking high doses of inhaled corticosteroids","volume":"105","author":"Tamaoki","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejpb.2025.114870_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110079","article-title":"Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution","volume":"144","author":"Garc\u00eda","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejpb.2025.114870_b0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11588150-000000000-00000","article-title":"Targeting airway inflammation in cystic fibrosis in children","volume":"13","author":"Pressler","year":"2011","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.ejpb.2025.114870_b0090","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1002\/ctd2.204","article-title":"Repurposing inhaled ibuprofenate, a non steroidal anti-inflammatory drug, as a potential adjuvant treatment for pneumonia, CARDS and its aetiological agent SARS-CoV-2","volume":"3","author":"Zurita-Lizza","year":"2023","journal-title":"Clin. Trans. Discov."},{"key":"10.1016\/j.ejpb.2025.114870_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/life12030356","article-title":"Piceatannol affects gastric ulcers induced by indomethacin: association of antioxidant, anti-inflammatory, and angiogenesis mechanisms in rats","volume":"12","author":"Shaik","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.ejpb.2025.114870_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-47508-8","article-title":"Efficacy of ibuprofen and indomethacin as prophylaxis of heterotopic ossification: a comparative study","volume":"13","author":"Schneider","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2025.114870_b0105","unstructured":"S. Bianco, US6051566. Anti-reactive anti-asthmatic activity of non-steroidal anti-inflamatory drugs by inhalation, 2000."},{"key":"10.1016\/j.ejpb.2025.114870_b0110","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-023-02528-5","article-title":"Good practices for the laboratory performance testing of aqueous oral inhaled products (OIPs): an assessment from the international pharmaceutical aerosol consortium on regulation and science (IPAC-RS)","volume":"24","author":"Mitchell","year":"2023","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.ejpb.2025.114870_b0115","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaerosci.2016.05.005","article-title":"Ibuprofen, indomethacin and diclofenac sodium nanoaerosol: Generation, inhalation delivery and biological effects in mice and rats","volume":"100","author":"Onischuk","year":"2016","journal-title":"J. Aerosol. Sci."},{"key":"10.1016\/j.ejpb.2025.114870_b0120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/03639045.2016.1253727","article-title":"Implementation of design of experiments approach for the micronization of a drug with a high brittle\u2013ductile transition particle diameter","volume":"43","author":"Yazdi","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0125","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/pharmaceutics16101269","article-title":"Feasibility of a high-dose inhaled indomethacin dry powder with dual deposition for pulmonary and oral delivery","volume":"16","author":"Spahn","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114870_b0130","first-page":"8","article-title":"A practical guide on the use of inhaler devices for asthma and COPD","author":"Salvi","year":"2021","journal-title":"Supplement J. Assoc. Physicians India"},{"key":"10.1016\/j.ejpb.2025.114870_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874306401408010001","article-title":"Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device","volume":"8","author":"Elkins","year":"2014","journal-title":"Open Respir. Med. J."},{"key":"10.1016\/j.ejpb.2025.114870_b0140","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1021\/acs.molpharmaceut.3c00395","article-title":"Inhalable excipient-free dry powder of tigecycline for the treatment of pulmonary infections","volume":"20","author":"Nair","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.msec.2014.04.040","article-title":"New alginic acid-atenolol microparticles for inhalatory drug targeting","volume":"41","author":"Ceschan","year":"2014","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ejpb.2025.114870_b0150","unstructured":"<1174> POWDER FLOW, in: USP44-NF39, 2021."},{"key":"10.1016\/j.ejpb.2025.114870_b0155","unstructured":"<601> INHALATION AND NASAL DRUG PRODUCTS: AEROSOLS, SPRAYS, AND POWDERS\u2014PERFORMANCE QUALITY TESTS, in: USP44-NF39, 2021."},{"key":"10.1016\/j.ejpb.2025.114870_b0160","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1021\/acs.molpharmaceut.7b00690","article-title":"Excipient-free pulmonary delivery and macrophage targeting of Clofazimine via air jet micronization","volume":"14","author":"Brunaugh","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.powtec.2023.119168","article-title":"Levofloxacin dry powder inhaler for high dose delivery","volume":"432","author":"Ceschan","year":"2024","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2025.114870_b0170","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1208\/s12249-014-0126-7","article-title":"In Vitro and In Vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization","volume":"15","author":"Wang","year":"2014","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.ejpb.2025.114870_b0175","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.redox.2018.03.006","article-title":"N-acetyl cysteine reverts the proinflammatory state induced by cigarette smoke extract in lung Calu-3 cells","volume":"16","author":"Valdivieso","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejpb.2025.114870_b0180","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/10837450.2019.1608449","article-title":"Jet milling industrialization of sticky active pharmaceutical ingredient using quality-by-design approach","volume":"24","author":"Nakach","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2025.114870_b0185","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijpharm.2008.09.029","article-title":"Spray drying of budesonide, formoterol fumarate and their composites-II. Statistical factorial design and in vitro deposition properties","volume":"367","author":"Tajber","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0190","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1016\/j.jnoncrysol.2006.02.130","article-title":"Transformations of glassy indomethacin induced by ball-milling","volume":"352","author":"Desprez","year":"2006","journal-title":"J. Non Cryst. Solids"},{"key":"10.1016\/j.ejpb.2025.114870_b0195","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/mp300390m","article-title":"Molecular understanding of the compaction behavior of indomethacin polymorphs","volume":"10","author":"Khomane","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0200","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.powtec.2012.07.004","article-title":"Dissolution enhancement of indomethacin via amorphization using co-milling and supercritical co-precipitation processing","volume":"240","author":"Lim","year":"2013","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2025.114870_b0205","doi-asserted-by":"crossref","DOI":"10.1007\/s11051-012-1275-9","article-title":"Indomethacin nanocrystals prepared by different laboratory scale methods: effect on crystalline form and dissolution behavior","volume":"14","author":"Martena","year":"2012","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ejpb.2025.114870_b0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jmatprotec.2007.11.086","article-title":"Mechanochemistry of silica on jet milling","volume":"205","author":"Palaniandy","year":"2008","journal-title":"J. Mater. Process Technol."},{"key":"10.1016\/j.ejpb.2025.114870_b0215","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1208\/s12249-017-0722-4","article-title":"Influence of drug brittleness, nanomilling time, and freeze-drying on the crystallinity of poorly water-soluble drugs and its implications for solubility enhancement","volume":"18","author":"Colombo","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2025.114870_b0220","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12247-017-9285-x","article-title":"Assistance for predicting deposition of tranilast dry powder in pulmonary airways by computational fluid dynamics","volume":"12","author":"Kadota","year":"2017","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.ejpb.2025.114870_b0225","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ejpb.2022.07.008","article-title":"Gelation switch of polyamorphic indomethacin depending on the thermal procedure","volume":"177","author":"Shen","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0230","doi-asserted-by":"crossref","DOI":"10.5826\/mrm.2024.960","article-title":"Usability of inhaler devices: a parameter currently misused","volume":"19","author":"Dal Negro","year":"2024","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.ejpb.2025.114870_b0235","doi-asserted-by":"crossref","DOI":"10.4081\/mrm.2021.752","article-title":"The contribution of patients\u2019 lung function to the inspiratory airflow rate achievable through a DPIs\u2019 simulator reproducing different intrinsic resistance rates","volume":"16","author":"Dal Negro","year":"2021","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.ejpb.2025.114870_b0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.03.006","article-title":"Emerging inhalation aerosol devices and strategies: where are we headed?","volume":"75","author":"Zhou","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2025.114870_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jamp.2019.1556","article-title":"The confusing world of dry powder inhalers: it is all about inspiratory pressures, not inspiratory flow rates","volume":"33","author":"Clark","year":"2020","journal-title":"J. Aerosol. Med. Pulm. Drug. Deliv."},{"key":"10.1016\/j.ejpb.2025.114870_b0250","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/03639045.2017.1318902","article-title":"Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients","volume":"43","author":"Akdag Cayli","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0255","first-page":"1","article-title":"Development and evaluation of paclitaxel and curcumin dry powder for inhalation lung cancer treatment","volume":"13","author":"Lee","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114870_b0260","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2016.02.030","article-title":"Hollow crystalline straws of diclofenac for high-dose and carrier-free dry powder inhaler formulations","volume":"502","author":"Yazdi","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0265","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijpharm.2008.08.017","article-title":"Aerosolization behavior of carrier-free l-leucine coated salbutamol sulphate powders","volume":"365","author":"Raula","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.powtec.2024.119565","article-title":"CFD-DEM investigation of the dispersion of elongated particles in the Turbuhaler\u00ae aerosol device","volume":"437","author":"Zhu","year":"2024","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2025.114870_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/3921426","article-title":"Dry Powder and budesonide inhalation suspension deposition rates in asthmatic airway-obstruction regions","volume":"2019","author":"Murayama","year":"2019","journal-title":"J. Drug. Deliv."},{"key":"10.1016\/j.ejpb.2025.114870_b0280","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejpb.2015.07.016","article-title":"Can \u201cextrafine\u201d dry powder aerosol improve lung deposition?","volume":"96","author":"de Boer","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0285","doi-asserted-by":"crossref","first-page":"588","DOI":"10.21037\/atm-20-5665","article-title":"Aerosol delivery via invasive ventilation: a narrative review","volume":"9","author":"Lin","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejpb.2025.114870_b0290","doi-asserted-by":"crossref","unstructured":"J.P. Mitchell, T.P. Tougas, The AIM and EDA Concepts: Why They Are Needed and How They Fit Together, in: T.P.T.\u2022 J.P. Mitchell, S.A. Lyapustina (Eds.), Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products, 1st ed., 2013: pp. 119\u2013134. doi: 10.1007\/978-1-4614-6296-5.","DOI":"10.1007\/978-1-4614-6296-5_5"},{"key":"10.1016\/j.ejpb.2025.114870_b0295","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.4187\/respcare.07237","article-title":"The relevance of targeting treatment to small airways in asthma and copd","volume":"65","author":"Santus","year":"2020","journal-title":"Respir. Care"},{"key":"10.1016\/j.ejpb.2025.114870_b0300","unstructured":"M.W. Nagel, J.A. Suggett, J.P. Mitchell, Effect of recorded inhalation waveforms on the in vitro aerodynamic performance of a passive dry powder inhaler (DPI), in: Conference: International Society for Aerosols in Medicine (ISAM) Congress 2019, 2019. DOI: 10.13140\/RG.2.2.31066.39369."},{"key":"10.1016\/j.ejpb.2025.114870_b0305","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3109\/02770903.2015.1028075","article-title":"Evaluation of inhaler technique, adherence to therapy and their effect on disease control among children with asthma using metered dose or dry powder inhalers","volume":"52","author":"Capanoglu","year":"2015","journal-title":"J. Asthma"},{"key":"10.1016\/j.ejpb.2025.114870_b0310","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijpharm.2018.06.006","article-title":"Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy","volume":"548","author":"Buttini","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114870_b0315","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jconrel.2020.04.015","article-title":"Excipient-free pulmonary insulin dry powder: pharmacokinetic and pharmacodynamics profiles in rats","volume":"323","author":"Quarta","year":"2020","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2025.114870_b0320","first-page":"330","article-title":"Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1 beta and tumour necrosis factor-alpha","volume":"77","author":"Cromwell","year":"1992","journal-title":"Immunology"},{"key":"10.1016\/j.ejpb.2025.114870_b0325","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1208\/s12249-009-9290-6","article-title":"Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study","volume":"10","author":"Naikwade","year":"2009","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.ejpb.2025.114870_b0330","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","article-title":"Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution","volume":"60","author":"Rennard","year":"1985","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ejpb.2025.114870_b0335","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10928-022-09824-w","article-title":"Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans","volume":"49","author":"Jagdale","year":"2022","journal-title":"J. Pharmacokinet Pharmacodyn."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125002474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125002474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T01:39:37Z","timestamp":1759628377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125002474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":67,"alternative-id":["S0939641125002474"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114870","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flowrate-Independent indomethacin dry powder inhaler for potential treatment of pediatric asthma: In vitro aerodynamic and anti-inflammatory evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114870"}}